Supernus Pharmaceuticals (SUPN) Cash from Financing Activities (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Cash from Financing Activities data on file, last reported at $9.1 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $9.1 million, up 142.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.6 million (up 467.89% YoY), and the FY2025 annual result was $9.1 million, down 25.12% from the prior year.
• Cash from Financing Activities climbed to $9.1 million in Q1 2026 per SUPN's latest filing, from $8.5 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $80.2 million in Q1 2023 and troughed at -$478.9 million in Q2 2023.
• A 5-year average of -$22.2 million and a median of $2.3 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities slumped 21169.78% in 2023, then jumped 1436.96% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $2.8 million in 2022, then plunged by 61.4% to $1.1 million in 2023, then surged by 439.38% to $5.9 million in 2024, then surged by 44.75% to $8.5 million in 2025, then climbed by 6.91% to $9.1 million in 2026.
• Business Quant data shows SUPN's Cash from Financing Activities at $9.1 million in Q1 2026, $8.5 million in Q4 2025, and $21.1 million in Q3 2025.